Types de Douleurs : Comprendre, Identifier et Traiter en 2025 - Séréni'café Comprendre les types de douleurs est essentiel pour mieux les prendre en charge; La douleur chronique touche aujourd'hui 42% des adultes français, soit plus

Types de Douleurs : Comprendre, Identifier et Traiter en 2025
42 % des Français souffrent de douleur chronique en 2025. 📉

L'espoir : la #Suzetrigine (antalgique non-opioïde) et la neurostimulation.

#DouleurChronique #Sante #Innovation #Soin

sereni-cafe.fr/les-differen...

#Suzetrigine (VX-548), a selective Nav 1.8 blocker, provides effective perioperative #pain relief with fewer side effects. Is this a promising non-opioid alternative?

www.bjanaesthesia.org/article/S000...

Texas Hospital Uses New Non‑Opioid Painkiller for Post‑Surgery Care

UT Health San Antonio adds FDA‑approved non‑opioid suzetrigine (Journavx) to its formulary, becoming the first Texas hospital to use it for post‑surgery pain after April rollout. Read more: getnews.me/texas-hospital-uses-new-... #suzetrigine #texas

Watch my interview on @cbcnews-rss.bsky.social about the new non-opioid painkiller #suzetrigine

youtube.com/watch?v=KfJX...

The first non-opioid painkiller Journavx was approved this year. Why did it take so long to develop?

Fascinating news!

First painkiller that's NOT opioid/related

#suzetrigine aka #Journavx works backwards
blocking pain signals from being transmitted in the first place

instead of blocking receptors

Unfortunately not yet tested/approved for chronic pain

and since no generic, for now expensive

The Radical Development of an Entirely New Painkiller The opioid crisis has made it even more urgent to come up with novel approaches to treating suffering. Finally there’s something effective.

#Suzetrigine (#Journavx) is the first new non-opioid painkiller in 20+ years approved for acute-pain treatment. It's unclear if it's helpful with chronic pain, cancer pain, or neuropathic pain. At $15 per pill, it's more expensive than a generic #opioid.

Pain relief without addiction? FDA approves first non-opioid alternative in decades For decades, opioids have been the gold standard for pain relief. However, long-term use comes with significant risks. The FDA recently approved a new drug to treat pain; the first to receive federal ...

🔗 www.womeninneuroscienceuk.org/post/pain-re...

#NeuroScience #PainRelief #Suzetrigine #ScienceNews #PublicHealth
(2/2)

Exciting new work on #suzetrigine effects on spontaneously active human DRG neurons from patients/donors with a pain history. Short story is that suzetrigine is remarkably effective at blocking spontaneous activity. Collab with Dougherty lab at MDACC!

Painkillers without the addiction? The new wave of non-opioid pain relief Pharma firms are developing drugs that avoid the brain’s opioid receptors to minimise the risks of dependence and overdoses, but not all experts are convinced

#pain #nonopioidpainrelief #drugdevelopment #suzetrigine #VertexPharmaceuticals #Vertex #Journavx #nonaddictivepainkiller #nociceptivepain #neuropathicpain #Nociplasticpain #chronicpain #dopamine #dopaminedump #VertexPharmaceuticals #TrisPharma #Vertanical
www.theguardian.com/science/2025...

Revolutionizing Pain Care: Suzetrigine and Other Innovations in Analgesia Podcast Episode · Vital Times: The CSA Podcast · 02/11/2025 · 24m

Catch last month’s @csahq.bsky.social podcast # vital times on the new nonopioid analgesic #suzetrigine podcasts.apple.com/us/podcast/v...
#pain.sky #anesthesia

Discovering Suzetrigine: A New Era in Pain Relief Suzetrigine: A Safer Nonopioid Analgesic In the ever-evolving world of pain management, a groundbreaking development has emerged that could change the landscape of treatment for millions of individuals suffering from acute pain. Suzetrigine, the first nonopioid analgesic approved by the FDA in 25 years, is generating excitement among pain specialists like Dr. Brett Stacey, a seasoned expert in the field and a professor of anesthesiology and pain medicine at the University of Washington School of Medicine.

READ FULL ARTICLE ON PAIN ON-LINE: #Suzetrigine #NonopioidAnalgesic #PainManagement #FDAApproval #AcutePain #PainRelief #ClinicalTrials #SodiumChannels #VertexPharmaceuticals #ChronicPain #OpioidAlternatives #PatientSafety #QualityOfLife #InnovativeTreatments #Pain #Medicine #Opioid

New pain medication has been FDA-approved In a groundbreaking development, the FDA has approved Vertex's suzetrigine for the treatment of moderate to severe acute pain. This approval marks the introduction of a pain medication to the market i...

The FDA approval of @vertexpharm.bsky.social #suzetrigine is a groundbreaking development. Hopes for patients with pain, and a lesson to pain researchers.
#PainManagement #DrugDevelopment

www.michelecuratolomd.com/post/a-new-d...

All-in-one virtual event platform | Zoom Events

On Friday, Feb 28 at 11 AM ET, join us for the virtual public meeting on the comparative clinical effectiveness and value of #suzetrigine (Journavx™, Vertex Pharmaceuticals) for the treatment of acute pain.

Register here: shorturl.at/YfAnp

No Opioids, No Addiction: FDA Approves First New Type of Painkiller in Decades Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.

This is really a big deal: No Opioids, No Addiction: FDA Approves First New Type of Painkiller in Decades https://buff.ly/4hTykIo #newpainkiller #painkiller #suzetrigine #journavx

Specialist explains intrigue of new pain-relief drug - UW Medicine | Newsroom Latest posts.css-qer9p{display:block;max-width:56px;height:4px;background-color:#f6b600;border-radius:8px;margin-top:8px;}

““I would bet that in a couple of years, we could sit down and have this conversation, and that either this #medication ..is now approved for some #chronicpain conditions,” Stacey said..“But we're not there yet"": https://buff.ly/4hU9f00 #suzetrigine #PainRelief #opioids

F.D.A. Approves Drug to Treat Pain Without Opioid Effects The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.

🧪 The FDA just approved #suzetrigine 💊 — a revolutionary nonaddictive pain reliever. The science behind it? Decades of research led by @yaleschoolofmed.bsky.social's Dr. Stephen Waxman, who pioneered its development in the late 1990s right here @yale.edu!

Read More 👇

Breakthrough painkiller treatment approved A game-changing painkiller – the first in 30 years that is not based on potentially addictive opioids – has been approved by regulators in the US.Treating pain is a huge global healthcare challenge an...

💊 A game-changing #painkiller (the first in 30 years not based on potentially addictive opioids) has been approved by US regulators.

🐁🐀 Rodent studies were the first to show that #suzetrigine could block pain signalling in the GI tract. #AnimalResearch
www.eara.eu/post/breakth...

Nonopioid drug for acute pain wins FDA approval Ongoing trials will reveal whether suzetrigine is also effective against chronic pain

A landmark day for pain research! The FDA approved suzetrigine, a NaV1.8 blocker representing the first new class of pain drugs to be approved in over 20 years. #painresearch #suzetrigine #paintherapeutics www.science.org/content/arti... @margolislabnyu.bsky.social

Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.

In this interview with Patient Care Online, I discuss the new FDA-approved drug #suzetrigine and its potential role in perioperative multimodal #pain management: www.patientcareonline.com/view/pain-ex...

@asahq.bsky.social @csahq.bsky.social @stanfordanes.bsky.social

FDA Approves Journavx Drug to Treat Pain Without Addiction Risk The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.

New 1st in class, non opiate nonNSAID ,

#peripheral #Pain medicine : #Journavx #suzetrigine

Might be kidney processed.

www.nytimes.com/2025/01/30/h...

#CPP #SFN #SmallFiberNeuropathy #DisabilitySky #NEisvoid

#Fibro #Neuropathy

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain #MECFS #LongCovid #suzetrigine

www.fda.gov/news-events/...

FDA approves first new type of pain medication in 25 years | CNN A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

#FDA approves 1st new type of #pain medication in 25yrs

Unlike opioids, which dull the sensation of pain, #suzetrigine works by preventing pain-signaling nerves from firing in the 1st place, so even tho the tissue injury exists, the brain doesn’t know.

#ChronicPain

www.cnn.com/2025/01/30/h...

FDA Approves Journavx Drug to Treat Pain Without Addiction Risk The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.

A remarkable journey of discovery, now an FDA-approved non-opioid drug that inhibits sodium channels in nerves to prevent pain signaling.

#Suzetrigine
#Vertex